Biopsia líquida y biomarcadores multiómicos en el cáncer de mama: innovaciones en la detección temprana, la orientación terapéutica y el seguimiento de la enfermedad

Simple item page
dc.contributor.authorReytor Gonzalez , Claudia Maria
dc.contributor.authorSimancas Racines , Daniel Alejandro
dc.contributor.authorRomán Galeano , Náthaly Mercedes
dc.contributor.authorVásquez , Juan Pablo
dc.contributor.authorJima Gavilanes , Dolores Alexandra
dc.contributor.authorRupalakshmi , Vijayan
dc.contributor.correspondingReytor Gonzalez , Claudia Maria
dc.date.accessioned2026-07-15T17:42:37Z
dc.date.available2026-07-15T17:42:37Z
dc.date.issued2026
dc.date.issued12/12/2025
dc.description.abstractLiquid biopsy and multi-omic biomarker integration are transforming precision oncology in breast cancer, providing real-time, minimally invasive insights into tumor biology. By analyzing circulating tumor DNA, circulating tumor cells, exosomal non-coding RNAs, and proteomic or metabolomic profiles, clinicians can monitor clonal evolution, therapeutic response, and recurrence risk in real time. Recent advances in sequencing technologies, methylation profiling, and artificial intelligence–driven data integration have markedly improved diagnostic sensitivity and predictive accuracy. Multi-omic frameworks com bining genomic, transcriptomic, and proteomic data enable early detection of resistance, molecular stratification, and identification of actionable targets, while machine learning models enhance outcome prediction and therapy optimization. Despite these advances, key challenges persist. Pre-analytical variability, lack of standardized protocols, and disparities in access continue to limit reproducibility and clinical adoption. High costs, incomplete regulatory validation, and the absence of definitive evidence for mortality reduction un derscore the need for larger, prospective trials. Integrating multi-omic assays into clinical workflows will require robust bioinformatics pipelines, clinician-friendly reporting sys tems, and interdisciplinary collaboration among molecular scientists, data engineers, and oncologists. In the near future, liquid biopsy is expected to complement, not replace, traditional tissue analysis, serving as a cornerstone of adaptive cancer management. As sequencing becomes faster and more affordable, multi-omic and AI-driven analyses will allow earlier detection, more precise treatment adjustments, and continuous monitoring across the disease course. Ultimately, these innovations herald a shift toward real-time, data-driven oncology that personalizes breast cancer care and improves patient outcomes.
dc.id.author1719015636
dc.id.author0502274095
dc.id.author1721511523
dc.id.author0703612358
dc.identifier.citation"Citation: Simancas-Racines, D.;Román-Galeano, N.M.; Vásquez, J.P.;Jima Gavilanes, D.; Vijayan, R.;Reytor-González, C. Liquid Biopsy and Multi-Omic Biomarkers in BreastCancer: Innovations in EarlyDetection, Therapy Guidance, and Disease Monitoring. Biomedicines 2025, 13, 3073. https://doi.org/10.3390/biomedicines13123073"
dc.identifier.doihttps://doi.org/10.3390/biomedicines13123073
dc.identifier.issn2227-9059
dc.identifier.urihttps://www.mdpi.com/2227-9059/13/12/3073
dc.identifier.urihttps://repositorio.puce.edu.ec/handle/123456789/49336
dc.indexed.databaseScopus
dc.language.isoen
dc.magazine.pageRange1-32
dc.magazine.titleCódigo Científico Revista de Investigación
dc.magazine.volumeChapterV13 NO. 12
dc.statePublished
dc.subjectBreast cancer
dc.subjectMulti-omic biomarkers
dc.subjectLiquid biopsy
dc.subjectPrecision medicine
dc.subjectHealthcare
dc.titleBiopsia líquida y biomarcadores multiómicos en el cáncer de mama: innovaciones en la detección temprana, la orientación terapéutica y el seguimiento de la enfermedad
dc.title.alternativeLiquid biopsy and multi-omic biomarkers in breast cancer: innovations in early detection, therapy guidance, and disease monitoring
dc.typeArtículo científico
Files
Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
39. Biopsia líquida y biomarcadores multiómicos en el cáncer de mama Innovaciones en la detección precoz, la orientación terapéutica y el seguimiento de la enfermedad.pdf
Size:
1.13 MB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed to upon submission
Description:
Download
Collections
Artículos científicos